Tribun Health Achieves FDA Clearance for CaloPix Digital Pathology Platform With Dual Scanner Compatibility
PARIS, FRANCE / ACCESS Newswire / May 20, 2025 / Tribun Health, a leader in digital pathology, proudly announces that its flagship web-based image management system, CaloPix®, has received FDA 510(k) clearance for use with two leading whole slide imaging scanners: the Hamamatsu NanoZoomer S360 and the Leica Aperio GT450. This marks the first time a digital pathology software has been cleared with both scanners, representing a major step forward for the U.S. adoption of vendor-agnostic, enterprise-grade solutions.
This clearance builds on CaloPix's strong regulatory track record: the solution is CE-marked, Health Canada-approved, and trusted by more than 100 hospitals and laboratories across Europe and Canada. With over 1,000 active users of CaloPix® worldwide, this milestone underscores the platform's scalability, clinical reliability, and rapid adoption across diverse healthcare systems. Now, with FDA clearance secured, Tribun Health is ready to bring its proven enterprise solution to hospitals and labs across the United States.
Besides these regulatory achievements, CaloPix® has also been recognized three times as "Best in KLAS" for digital pathology, a global benchmark for excellence in healthcare IT. This prestigious recognition highlights Tribun Health's commitment to customer satisfaction, operational excellence, and product innovation.
"This is a major commercial and clinical milestone for us," said Jean-François Pomerol, CEO of Tribun Health. "We're entering the U.S. with a solution that has already proven its value in demanding, high-throughput clinical environments. With CaloPix®, we offer a platform trusted by top-tier institutions, awarded Best in KLAS multiple times -and now validated by the FDA. As the market accelerates toward widespread clinical adoption, we're thrilled to expand our reach and solidify our position as a truly global player."
Built for Enterprise, Designed for Performance, Ready for Cloud
CaloPix® goes far beyond a traditional image viewer-it's a powerful, all-in-one digital pathology platform tailored for the needs of modern healthcare systems, large hospital networks, and academic institutions.
Key capabilities include:
Web-based, Cloud ready, zero-footprint architecture-no local installation requiredHigh-throughput case management and diagnostic reporting to streamline daily workflowsSeamless integration with LIS and VNA systems for unified data access across the enterpriseBuilt-in telepathology and remote collaboration tools for second opinions and network-wide consultationsArchiving, export, and quality control features to support regulatory compliance and research initiatives
Meeting the Moment: Solving U.S. Market Challenges
The U.S. faces a growing mismatch between rising pathology case volumes and a shrinking workforce. At the same time, there is a clear push for multi-site collaboration, integrated diagnostics, and precision medicine initiatives.
With this FDA clearance, CaloPix® empowers U.S. hospitals and labs to:
Digitize pathology workflows at scaleReduce turnaround times and improve reporting accuracyCollaborate remotely across institutionsPrepare for AI adoption with structured, interoperable data
Building on our success with public health networks, cancer centers, academic hospitals and private laboratory groups across Europe and Canada, we are now ready to scale in the world's largest healthcare market-the United States.
* CaloPix® is CE mark, HC cleared, FDA cleared. Please refer to IFU for intended use.
About Tribun Health
Tribun Health is a global leader in digital pathology, offering award-winning solutions that improve workflow efficiency, diagnostic accuracy, and patient outcomes. We assist hospitals and laboratories in transitioning from glass slide pathology to fully digital solutions, leveraging AI and data-driven technology to enhance precision and reduce turnaround times. Our mission is simple: to ensure every cancer patient receives a timely and informed diagnosis-because every moment counts. By advancing pathology with cutting-edge innovations, we are shaping the future of cancer care. For more information, visit Tribun Health and follow us on LinkedIn and X.
Contact Information
Andreia Beyer VP, Global Marketing & Managing Director, North Americaabeyer@tribun.health+1 (416) 565-0474
SOURCE: Tribun Health
press release
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Fast Company
8 minutes ago
- Fast Company
Over 67,000 cases of popular deodorant recalled nationwide
The products, Power Stick roll-on deodorants, are made by the Easton, Pennsylvania-based company A.P. Deauville. Per an enforcement notice, the recall includes three separate products: the Power Stick For Her Roll-On Antiperspirant Deodorant in the scent 'power fresh,' the Power Stick Invisible Protection Roll-On Antiperspirant Deodorant in the scent 'spring fresh,' and the Power Stick Original Nourishing Invisible Protection Roll-On Antiperspirant Deodorant. Over 20,000 cases of each product were recalled. The enforcement notice marked the reason for the recall as 'cGMP deviations', which stands for Current Good Manufacturing Practice. Per the FDA website, failure to meet CGMP regulations can lead to products being recalled. The FDA notes, 'Adherence to the CGMP regulations assures the identity, strength, quality, and purity of drug products by requiring that manufacturers of medications adequately control manufacturing operations. This includes establishing strong quality management systems, obtaining appropriate quality raw materials, establishing robust operating procedures, detecting and investigating product quality deviations, and maintaining reliable testing laboratories.' The recall was announced on July 10 and is ongoing. While the products did not meet FDA standards, an exact reason for the recall was not disclosed. No injuries have been reported. According to the enforcement report, the products were distributed nationwide. They are regularly sold at Dollar Tree, Amazon, and Walmart.
Associated Press
11 minutes ago
- Associated Press
RetailNOW and the Kiosk Industry Association – Visit Booth 445 for AI-Assist, Kiosks and Digital Signage
WESTMINSTER, Colo. and LAS VEGAS, July 21, 2025 (SEND2PRESS NEWSWIRE) — Come see Kiosk Industry in booth 445. Conversational AI hardware and AI analytics hardware highlighted. meldCX for Windows and Android for device support and analytics. AI Connect Bar provides hardware for conversational AI used in drive-thrus, help desks, and self-ordering. Augment your solution. We thank Intel and Kathy Crumley. Kathy is leading one of the expert panels. This event is NOT open to the general public. Kathy email — [email protected]. To set up a time to meet or request info, email [email protected] 2025 EDITION OF RETAILNOW SHOW — In The Booth Virtual Supporters News This Month Show information: Thanks to the companies who make this possible. Learn more: MEDIA CONTACT: Craig Keefner [email protected] NEWS SOURCE: Kiosk Industry Group Keywords: Point of Sale and Kiosks, RetailNOW Las Vegas, Kiosk Industry Association, AI-Assist, Kiosks and Digital Signage, WESTMINSTER, Colo. and LAS VEGAS This press release was issued on behalf of the news source (Kiosk Industry Group) who is solely responsibile for its accuracy, by Send2Press® Newswire. Information is believed accurate but not guaranteed. Story ID: S2P127886 APNF0325A To view the original version, visit: © 2025 Send2Press® Newswire, a press release distribution service, Calif., USA. RIGHTS GRANTED FOR REPRODUCTION IN WHOLE OR IN PART BY ANY LEGITIMATE MEDIA OUTLET - SUCH AS NEWSPAPER, BROADCAST OR TRADE PERIODICAL. MAY NOT BE USED ON ANY NON-MEDIA WEBSITE PROMOTING PR OR MARKETING SERVICES OR CONTENT DEVELOPMENT. Disclaimer: This press release content was not created by nor issued by the Associated Press (AP). Content below is unrelated to this news story.
Yahoo
11 minutes ago
- Yahoo
Sarepta refuses to pull gene therapy despite FDA order
Sarepta Therapeutics is refusing to pull its gene therapy Elevidys (delandistrogene moxeparvovec), despite a request from the US Food and Drug Administration (FDA). Speaking on 18 July, shortly after the FDA ordered the pull for Elevidys, Sarepta said it will continue to ship Elevidys to the ambulant population as studies show no signs of new or changed safety signals, adding it first heard of this potential request earlier in the day through media reports. A statement from the company reads: 'At Sarepta, patient safety and well-being are always our top priority. We are committed to upholding the highest safety standards for all of our therapies. "This guides every decision we make, as evidenced by our conservative decision to pause shipments of Elevidys for non-ambulant patients while we work with the FDA to update the label and evaluate the use of an enhanced immunosuppression regimen to mitigate the risk of acute liver failure (ALF).' Trial of LGMD therapy also put on hold The FDA has also put a hold on Sarepta's gene therapy SRP-9004 in limb girdle muscular dystrophy (LGMD) after a patient died in an early-stage study due to ALF. Speaking about the patient death in the Phase I trial of SRP-9004, the company's statement added: 'We recognise that the death of any patient is heartbreaking, including the recent death of a 51-year-old non-ambulant LGMD patient. "We also want to clarify that this tragic event occurred in a Phase I clinical trial for an investigational gene therapy called SRP-9004. SRP-9004 is a clinical-stage therapy that is intended to treat a different disease, is administered using a different dose, and is manufactured using a different process. The LGMD study participant who passed away was not treated with Elevidys, and the dosing for the SRP-9004 trial had concluded at the time of his death.' This patient's death, which was reported to the FDA on 3 July, is the third that has impacted Sarepta's gene therapy programme, with the first two deaths earlier this year in patients treated with Elevidys, both also due to ALF. Both Elevidys and SRP-9004 are adeno-associated virus (AAV) gene therapies that use the same AAVrh74 serotype. The FDA's Center for Biologics Evaluation and Research (CBER) director Dr Vinay Prasad, said: 'Protecting patient safety is our highest priority, and the FDA will not allow products whose harms are greater than benefits. The FDA will halt any clinical trial of an investigational product if clinical trial participants would be exposed to an unreasonable and significant risk of illness or injury.' This comes just days after Sarepta said it has agreed to change the black box on the Elevidys label to include ALF and acute liver injury (ALI) warnings. In the same announcement, Sarepta said it would be cutting 500 jobs as part of company restructuring. Speaking after the third patient death was announced, GlobalData healthcare analyst Momna Ali said the recent setbacks for Sarepta put the cell and gene therapy (CGT) sector at a 'crossroads'. Ali said: 'Following Sarepta's announcement of a third patient death, a new label for Elevidys and them laying off 500 employees, or 36% of its workforce, shelving parts of its pipeline to save $420m, and shifting focus from gene therapy to siRNA programmes, this is going to put the CGT sector at a pivotal crossroad. 'While the scientific potential of CGT therapies remains extraordinary, this moment serves as a reminder of the complexity, cost, and responsibility involved. There is a lot of buzz around therapies 'beyond the pill'; however, for the landscape to keep evolving at the pace it has been in the last 3-5 years, there has to be greater transparency, patient safety, and sustainable innovation – otherwise, it'll be met with more setbacks.' The news of the LGMD death came to light on 17 July in media reports. After this was reported, Sarepta's stock has dropped 43.21%, from $22.54 at market open on 17 July to $12.80 at market open on 21 July. The FDA also said it has revoked the platform technology designation for Sarepta's AAVrh74 Platform Technology. "Sarepta refuses to pull gene therapy despite FDA order" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
